PepPool: CEFRAS Global (CD4), human

Human PBMC (250,000 cells per well) stimulated with the CEFRAS Global (CD4) peptide pool in human IFN-γ ELISpot. Analysis was done with Mabtech IRIS.
Human PBMC (250,000 cells per well) stimulated for 48 hours with the CEFRAS Global (CD4) peptide pool in human IFN-γ/IL 4/IL-5 FluoroSpot. Analysis was done with Mabtech IRIS.
Human PBMC (250,000 cells per well) stimulated with the CEFRAS Global (CD4) peptide pool in human IFN‑γ/IL‑2/TNF‑α FluoroSpot. Analysis was done with Mabtech IRIS.

PepPool: CEFRAS Global (CD4), human

3627-1

Special offer

You may add one these complementary products at a reduced price.

This offer is valid when purchasing PepPool: CEFRAS Global (CD4), human or other qualifying products.

Publications: 0
Documents
Questions?
Validated for our assays.

In stock

Delivery 4-9 business days

Shipping $0

Product specifications

Intended use

This peptide pool is intended for use as a positive control in immunoassays such as ELISpot and FluoroSpot. It induces cytokine secretion from antigen-specific human CD4 T cells. For research use only. Not for use in diagnostic procedures.

Serum/Plasma samples

Description

The CEFRAS (CD4) peptide pool stimulates CD4+ T cells to produce e.g., IFN-γ, IL-2, IL-4, IL-5, and TNF-α. It is recommended as a positive control in ELISpot and FluoroSpot assays using human PBMC. The peptide pool can also be used in flow cytometry.

The 85 peptides in the pool are MHC class II restricted T-cell epitopes from twenty pathogens: Coxsackievirus B4, Clostridium tetani, Haemophilus influenza, Helicobacter pylori, Human adenovirus 5, Human herpesvirus 1, Human herpesvirus 2, Human herpesvirus 3, Human herpesvirus 4, Human herpesvirus 5, Human herpesvirus 6, Human papillomavirus, Influenza A, JC polyomavirus, Measles virus, Mycobacterium tuberculosis, Respiratory syncytical virus, SARS-CoV-2, Rubella virus, and Vaccinia virus. The peptide pool is designed for T cell stimulation, covering a broad range of HLA types from diverse ethnic backgrounds. Peptides are synthesized with capping after coupling. The median HPLC purity is 80%.

Recommendation

Product details

ProductPepPool: CEFRAS Global (CD4), human
ApplicationELISpot, FluoroSpot, T cell stimulation
ReactivityHuman
Supplied in

Lyophilized

Shipping and Storage

Shipping

Shipped at ambient temperature.

Storage

Store at -20 °C or below upon receipt. 

Human PBMC (250,000 cells per well) stimulated with the CEFRAS Global (CD4) peptide pool in human IFN-γ ELISpot. Analysis was done with Mabtech IRIS.

Human PBMC (250,000 cells per well) stimulated with the CEFRAS Global (CD4) peptide pool in human IFN-γ ELISpot. Analysis was done with Mabtech IRIS.

Human PBMC (250,000 cells per well) stimulated with the CEFRAS Global (CD4) peptide pool in human IFN-γ ELISpot. Analysis was done with Mabtech IRIS.
Human PBMC (250,000 cells per well) stimulated for 48 hours with the CEFRAS Global (CD4) peptide pool in human IFN-γ/IL 4/IL-5 FluoroSpot. Analysis was done with Mabtech IRIS.
Human PBMC (250,000 cells per well) stimulated with the CEFRAS Global (CD4) peptide pool in human IFN‑γ/IL‑2/TNF‑α FluoroSpot. Analysis was done with Mabtech IRIS.

Find out which analyte combinations we have evaluated in T cell FluoroSpot and which combinations are affected by capture effects or not. 

What is a capture effect?

When capture antibodies with different specificities are coated together, the capture of one cytokine may affect the secretion of other cytokines. This is usually more pronounced when studying T cell responses with polyclonal stimuli compared to antigen-specific responses. Capture effects are seldom a problem and can often be counteracted by the addition of an anti-CD28 antibody.

Depiction of capture effects observed in FluoroSpot

(1) IL-2 secreted by the activated T cell is captured by coated anti-IL-2 capture antibodies. (2) As a result, IL-2-stimulation of the T cell itself (autocrine stimulation) as well as nearby T cells (paracrine stimulation) is impaired, ultimately leading to (3) decreased IFN-γ secretion.

Co-stimulation with anti-CD28

Anti-CD28 mAb provides a co-stimulatory signal to antigen-specific responses by binding to CD28 on T cells. The addition of an anti-CD28 mAb to the cell culture enhances antigen-specific responses and can counteract capture effects. For example, the presence of IL-2 capture antibodies may result in reduced activation of T cells, as capturing of IL-2 decreases the amount of available IL-2 and thereby dampens the IL-2-mediated stimulation of T cells. The addition of anti-CD28 mAb restores IFN-γ responses (depicted in the below images). Further optimization may be necessary, depending on the cells and stimuli used. Too high concentrations of the anti-CD28 mAb may result in an elevation of non-specific cytokine secretion.

Overcoming capture effects using anti-CD28 anitbodies in FluoroSpot

(1) An anti-CD28 antibody can be added to provide a co-stimulatory signal that can restore (2) e.g. IFN-γ responses.

How to investigate capture effects

Our FluoroSpot Plus kits are evaluated for capture effects, and in studies of T cell responses we recommend co-stimulation with anti-CD28. With FluoroSpot Flex, it is possible to combine and build your own kit. For guidance look at our analyte combination table (above). Capture effects can be investigated by quantifying spot numbers in wells coated with single capture antibodies and compared to wells coated with a mixture of the capture antibodies. The compensatory effect of the anti-CD28 mAb may be assessed by comparing cells cultured with and without the anti-CD28 mAb.

Tutorial
Published: December 28, 2023 | 2 minute read

Incubation strategies for success in ELISpot and FluoroSpot

We've made a handy table summarizing incubation times for different analytes to make your research planning for the ELISpot and FluoroSpot assay a little easier.
Loading publications...